Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRK2 | P25098 | 20/20 | 1.00 |
| ▸ | ROCK1 | Q13464 | 16/20 | 1.00 |
| ▸ | GRK5 | P34947 | 14/20 | 1.00 |
| ▸ | GRK1 | Q15835 | 6/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17525422 | 0.94 | GRK2 (1.00) | GRK2ROCK1GRK5GRK1 | |
| SCHEMBL23083245 | 0.93 | GRK2 (0.86) | GRK2ROCK1GRK5GRK1 | |
| SCHEMBL17525425 | 0.91 | GRK2 (1.00) | GRK2ROCK1GRK5GRK1 | |
| SCHEMBL17525424 | 0.91 | GRK2 (1.00) | GRK2ROCK1GRK5GRK1 | |
| SCHEMBL17525411 | 0.91 | GRK2 (1.00) | GRK2ROCK1GRK5GRK1 | |
| SCHEMBL17525384 | 0.90 | GRK2 (1.00) | GRK2ROCK1GRK5GRK1 | |
| SCHEMBL17525387 | 0.90 | GRK2 (1.00) | GRK2ROCK1GRK5GRK1 | |
| SCHEMBL29705818 | 0.90 | GRK2 (1.00) | GRK2ROCK1GRK5GRK1 | |
| SCHEMBL17525423 | 0.90 | GRK2 (1.00) | GRK2ROCK1GRK5GRK1 | |
| SCHEMBL29705812 | 0.90 | GRK2 (1.00) | GRK2ROCK1GRK5GRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230035892-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | FLAGSHIP PIONEERING, INC. | 2023-02-02 | — | — | US | disclosed |
| WO-2021046225-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2021-03-11 | — | — | WO | disclosed |
| US-10023564-B2 | G protein-coupled receptor kinase 2 inhibitors and methods for use of the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-07-17 | — | — | US | disclosed |
| US-10023564-B2 | G protein-coupled receptor kinase 2 inhibitors and methods for use of the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-07-17 | — | — | US | disclosed |
| US-20170240538-A1 | G PROTEIN-COUPLED RECEPTOR KINASE 2 INHIBITORS AND METHODS FOR USE OF THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2017-08-24 | — | — | US | disclosed |
| US-20170240538-A1 | G PROTEIN-COUPLED RECEPTOR KINASE 2 INHIBITORS AND METHODS FOR USE OF THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2017-08-24 | — | — | US | disclosed |
| WO-2016023028-A2 | G PROTEIN-COUPLED RECEPTOR KINASE 2 INHIBITORS AND METHODS FOR USE OF THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10023564-B2 | G protein-coupled receptor kinase 2 inhibitors and methods for use of the same | GRK2, GRK4, GRK5 | GRK2 1/4885ROCK1 349/4885GRK5 3/4885 |
| US-20170240538-A1 | G PROTEIN-COUPLED RECEPTOR KINASE 2 INHIBITORS AND METHODS FOR USE OF THE SAME | GRK2, GRK4, GRK5 | GRK2 1/4885ROCK1 349/4885GRK5 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.